Solyx Sis System
Payments companies reported to CMS as associated with Solyx Sis System. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Solyx Sis System, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Solyx Sis System
These are the largest totals companies reported as associated with Solyx Sis System. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Thomas Giudice | West Columbia, SC | Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) | $76,352.80 |
| Elizabeth Williams | St. Louis, MO | Urogynecology and Reconstructive Pelvic Surgery (Urology) | $46,283.43 |
| Kevin Benson | Sioux Falls, SD | Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) | $31,050.22 |
| Michael Swan | Nashville, TN | Obstetrics & Gynecology | $29,666.40 |
| Brent Parnell | Birmingham, AL | Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) | $22,479.37 |
| Tara Allen | Nashville, TN | Urogynecology and Reconstructive Pelvic Surgery (Urology) | $21,071.73 |
| Dara Shalom | Great Neck, NY | Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) | $20,646.92 |
| Charbel Salamon | Orlando, FL | Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) | $20,422.13 |
| Nahla Merhi | New Lenox, IL | Gynecology | $20,245.69 |
| Christopher Tarnay | Los Angeles, CA | Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) | $19,410.79 |
Prescribed Solyx Sis System?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.